摘要：

REFERRED TO CRYSTALLINE STRUCTURE OF dapagliflozin selected from: (a) A structure of L-proline 1: 2 (FORM 3) with the following pattern of XRD POWDER (2Theta): 3.3 ± 0.1, 6.5 ± 0.1, 8.6 ± 0.1, 15.7 ± 0.1, 16.4 ± 0.1, 17.2 ± 0.1, 18.9 ± 0.1, 19.8 ± 0.1 and 20.3 ± 1; (B) a structure of L-proline 1: 1 (METHOD 6) with the following pattern of XRD POWDER (2Theta): 3.9 ± 0.1, 9.5 ± .1, 15.4 ± 0.1, 15.7 ± .1 15.9 ± 0.1 17.5 ± 0.1, 18.7 ± 0.1, 19.7 ± 0.1 and 20.3 ± 0.1; (C) A hemihydrate L-PROLINE STRUCTURE 1: 1 (FORM H.5-2) FOLLOWING WITH PATTERN XRD POWDER (2Theta): 3.9 ± 0.1, 8.8 ± 0.1, 15.5 ± 0.1, 15.8 ± 0.1, 16.5 ± 0.1, 17.8 ± 0.1, 19.4 ± 0.1, 19.7 ± 0.1 and 20.8 ± 0.1 and (D) a structure of L-FENILALANINA1: 1 (forma2). BESIDES referring to a pharmaceutical composition. CRYSTAL STRUCTURE SUCH IS A cotransporter inhibitor sodium-glucose type 2 (SGLT2) UTIL IN THE TREATMENT OF DIABETES

展开